<DOC>
	<DOCNO>NCT00557102</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Drugs use chemotherapy , irinotecan , leucovorin , fluorouracil , work different way stop growth tumor cell , either kill cell stop divide . Giving cetuximab together combination chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together combination chemotherapy work first-line therapy treat patient colorectal cancer spread liver and/or lung .</brief_summary>
	<brief_title>Cetuximab Combination Chemotherapy First-Line Therapy Treating Patients With Colorectal Cancer That Has Spread Liver and/or Lung</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine tumor response rate patient colorectal cancer hepatic and/or pulmonary metastasis treat cetuximab FOLFIRI chemotherapy comprise irinotecan hydrochloride , leucovorin calcium , fluorouracil first-line therapy . Secondary - Determine rate resectability patient treat regimen . - Determine overall disease-free survival patient treat regimen . - Determine tolerability regimen patient . OUTLINE : This multicenter study . Patients receive cetuximab IV 60-120 minute day 1 8 . Patients also receive FOLFIRI chemotherapy comprise irinotecan hydrochloride IV 90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 48 hour day 1 2 . Patients 7/6 7/7 genotype also receive filgrastim ( G-CSF ) primary prophylaxis ( patient 6/6 genotype receive G-CSF secondary prophylaxis ) . Treatment repeat every 2 week 8 course absence disease progression unacceptable toxicity . Within 6 week completion cetuximab FOLFIRI chemotherapy , patient respond disease undergo surgical resection visceral metastasis .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Must synchronous metasynchronous unresectable hepatic metastasis Less 8 hepatic metastasis Less 6 segment liver involvement metastases No 2 potentially resectable extrahepatic ( e.g. , pulmonary ) metastases Patients visceral metastasis potentially resectable chemotherapy ( i.e. , tumor regression ) eligible At least 1 measurable metastasis CT scan MRI No brain metastasis , bone metastasis , carcinomatous meningitis No celiac lymph node involvement peritoneal cancer PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 3 month ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ PT rate &gt; 70 % Bilirubin &lt; 30 μmol/L Creatinine &lt; 130 μmol/L Creatinine clearance &gt; 60 mL/min Not pregnant nursing No prior malignancy except basal cell skin cancer carcinoma situ cervix No severe unstable angina No symptomatic heart failure No concurrent illness PRIOR CONCURRENT THERAPY : At least 3 month since prior adjuvant anticancer chemotherapy No concurrent participation another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
</DOC>